Attovia Therapeutics

Attovia Therapeutics (Ticker: ATTO US) develops biologic medicines for immune-mediated diseases using its licensed ATTOBODY nanobody-based platform to support that work. ATTOBODY is a licensed nanobody-based platform used to develop biologic medicines for immune-mediated diseases. Its lead candidate, ATTO-1310, targets IL-31. Dosing in a Phase 1 trial involving healthy volunteers and patients with chronic pruritus and atopic dermatitis was completed in the first quarter of 2026. Attovia Therapeutics is headquartered in San Carlos, California, and incorporated in Delaware. The company has no approved products or product-sales revenue.

The scheduled listing date on Nasdaq was August 5, 2026. The proposed offering comprises 12,500,000 shares at an indicative price range of $15.00–17.00 per share. At the indicative range midpoint, the base offering would represent $200.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $616.00 million.

Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital are managing the offering.